Product Development Research Review Council
Roy Cosan, B.B.A.
Roy Cosan is President of Renova Therapeutics. Prior to joining Renova, he was a Managing Director at Fjord Ventures. Roy’s experience includes 32 years with Johnson and Johnson. He was Vice President of New Product Development at Janssen Pharmaceuticals where he launched Risperdal and Reminyl.
Roy was also a Vice President with the Johnson & Johnson Development Corp., the venture capital arm of J&J where he invested in 19 companies and held 11 board of director seats. Roy helped build a virtual R&D capability within J&J Pharma. He holds a B.B.A. with a concentration in marketing from Western Michigan University.
Jack Geltosky, Ph.D.
JEG and Associates, LLC
Jack has over 30 years of experience in the pharmaceutical industry, evenly split between R&D and licensing.
Jack was the Senior Vice President of Business Development for Arizona Technology Enterprises (AZTE), the technology transfer arm of Arizona State University, from 2007 to June of 2011. He now serves as a Senior Consultant to AZTE. Jack has been a part of CPRIT for seven years, the last two serving as Chairman of the Product Development Review Council.
Jack served on the Board of Directors of Enzon Pharmaceuticals from 2008-2009 and is currently on the Board of Sophiris Bio.
David Shoemaker, Ph.D.
Senior Vice President, Research and Development
David is currently responsible for developing and executing integrated product development strategies for products ranging from discovery through market approval. David serves as an advisor to multidisciplinary program teams, contributing regulatory perspectives on clinical, preclinical, and chemistry, manufacturing and controls development decisions.
David has participated in the development of the regulatory strategy for programs involving central nervous system products, blood products, oncology therapeutics and vaccines, gene and stem cell products, immunomodulators, cardiovascular therapeutics, and metabolic and endocrine therapeutics.
Sandra L. Silberman, M.D., Ph.D.
Independent Consultant to the Pharmaceutical/Biotech Industry, SLS Oncology, LLC
Attending Physician, Durham VA Medical Center
Dr. Silberman is a Hematologist/Oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, in Baltimore, MD. She received her M.D. from Cornell University Medical College in New York City, and then completed both a clinical fellowship in Hematology/Oncology as well as a research fellowship in tumor immunology at the Brigham & Women's Hospital and the Dana Farber Cancer Institute in Boston, MA. She continued to do basic research in Boston after being granted a Clinical Investigator Award from the National Institutes of Health and was an Instructor in Medicine at Harvard Medical School. She subsequently served as an attending physician at Yale University Hospital in New Haven, CT.
Neil L. Spector, M.D.
Co-Director: Developmental Therapeutics Program
Duke Cancer Institute
Dr. Neil Spector is currently Sandra P. Coates Associate Professor, Departments of Medicine and Pharmacology/Cancer Biology, Duke University School of Medicine; Associate Director, Clinical Research, Breast Cancer Program, Duke Cancer Institute; Co-Director, Developmental Therapeutics Program, Duke Cancer Institute
Dr. Spector received his B.S. from the University of North Carolina at Chapel Hill in 1978. After graduation, Dr. Spector completed his M.D. from the New Jersey Medical School in 1982 and his internal medicine residency at Parkland Hospital, University of Texas-Southwestern Medical School, Dallas, Texas. Dr. Spector then completed a hematology/medical oncology fellowship at the Massachusetts General Hospital/Dana Farber Cancer Center, Harvard Medical School.
Colin Turnbull, Ph.D.
Colin Turnbull Consulting LLC
Colin Turnbull is a native of Edinburgh, Scotland. He obtained a Bachelor’s degree in Pharmacy from Heriot-Watt University, Edinburgh, and a Ph.D. in Organic Chemistry from Aston University, Birmingham, England, the subject of his Doctoral thesis being the synthesis and chemical characterization of novel anti-tumor triazenes.
His career in the pharmaceutical industry spanned some 28 years during which he held increasingly senior positions in general management, Health Economics, and Clinical Research, culminating in his appointment as Vice President and Head of Global Oncology Clinical Research, Schering-Plough Research Institute (SPRI), and Chairman, Oncology Development Team, SPRI.
For the last 12 years, Dr. Turnbull has been an independent consultant specializing in carrying out due diligence assessment of oncology related investment opportunities for pharmaceutical and biotechnology industry clients and for venture capital firms.